AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and safety, AD 452 is being tested in a 3 month study. Patients enrolled in this study will already be taking methotrexate for their RA and they will remain on methotrexate throughout the study. An earlier clinical study in 98 subjects with RA on stable background therapy investigated the pharmacokinetics, safety and tolerability of AD 452 taken for one month. The drug was well tolerated and no significant drug related adverse events were reported.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
232
Clinical Research of West Florida, Inc
Clearwater, Florida, United States
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, United States
Ocala Rheumatology Research Center
Ocala, Florida, United States
Sarasota Arthritis Research Center
Sarasota, Florida, United States
Advent Clinical Research Centers, Inc.
St. Petersburg, Florida, United States
Dept of Rheumatology, Columbia Medical Practice
Columbia, Maryland, United States
Anderson and Collins Clinical Research, Inc.
Edison, New Jersey, United States
Station Avenue
Haddon Heights, New Jersey, United States
Atlantic Coast Research LLC
Toms River, New Jersey, United States
Rheumatic Disease Associates
Willow Grove, Pennsylvania, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.